1. Scrip
  2. >>R&D

Horizon Makes The Case For An Ambitious $10Bn Sales Goal

 
• By Jessica Merrill

The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.

Growth

Horizon Therapeutics plc’s acquisition of Viela Bio, Inc. earlier this year has resulted in a blossoming mid-stage pipeline and early R&D engine, and management showcased the expanded lineup at an R&D day on 29 September. Horizon CEO Timothy Walbert said that four mid-stage assets alone, along with Horizon's current commercial portfolio, could collectively generate peak annual net sales of $10bn.

"We expect 10 data readouts from 2021 to 2023 with 10 potential new medicine or new indication approvals in the second half of the decade," Walbert said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.